Do analysts prefer FRX or SLS?

Solaris Resources has a consensus price target of C$19.50, indicating a potential upside of 57.77%. Given Solaris Resources' higher possible upside, analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Solaris Resources 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend CARA or FRX?

Given Cara Operations' higher probable upside, equities research analysts plainly believe Cara Operations is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Operations 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has preferable valuation & earnings, CARA or FRX?

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cara Operations N/A N/A N/A N/A N/A Fennec Pharmaceuticals C$51.00M 10.43 -C$800.44K -C$0.29 N/A

Do analysts recommend FRX or CRON?

Cronos Group has a consensus price target of C$4.75, indicating a potential upside of 19.05%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, FRX or CRON?

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fennec Pharmaceuticals C$51.00M 10.43 -C$800.44K -C$0.29 N/A Cronos Group C$159.54M 9.35 -C$32.78M N/A N/A

Do analysts prefer FRX or TLRY?

Tilray Brands has a consensus target price of C$13.30, suggesting a potential upside of 103.99%. Given Tilray Brands' higher probable upside, analysts clearly believe Tilray Brands is more favorable than Fennec Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Tilray Brands 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer FRX or ITH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 International Tower Hill Mines 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Fennec Pharmaceuticals (FRX) Competitors

C$15.32 0.00 (0.00%)

As of 07/3/2026

Compare

FRX vs. SLS, CARA, CRON, TLRY, and ITH

Should you buy Fennec Pharmaceuticals stock or one of its competitors? MarketBeat compares Fennec Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fennec Pharmaceuticals include Solaris Resources (SLS), Cara Operations (CARA), Cronos Group (CRON), Tilray Brands (TLRY), and International Tower Hill Mines (ITH). These companies are all part of the "pharmaceutical products" industry.

How does Fennec Pharmaceuticals compare to Solaris Resources?

Fennec Pharmaceuticals (TSE:FRX) and Solaris Resources (TSE:SLS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Solaris Resources has a consensus price target of C$19.50, indicating a potential upside of 57.77%. Given Solaris Resources' higher possible upside, analysts clearly believe Solaris Resources is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Solaris Resources	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Fennec Pharmaceuticals has higher revenue and earnings than Solaris Resources. Solaris Resources is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	10.43	-C$800.44K	-C$0.29	N/A
Solaris Resources	N/A	N/A	-C$46.49M	-C$0.19	N/A

Solaris Resources has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Solaris Resources' return on equity of 60.97% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Solaris Resources	N/A	60.97%	-51.67%

13.1% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Solaris Resources shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by company insiders. Comparatively, 40.6% of Solaris Resources shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Solaris Resources had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 1 mentions for Solaris Resources and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Solaris Resources'average media sentiment score.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Solaris Resources	Neutral

Fennec Pharmaceuticals has a beta of 3.522795, suggesting that its share price is 252% more volatile than the broader market. Comparatively, Solaris Resources has a beta of 1.721408, suggesting that its share price is 72% more volatile than the broader market.

Summary

Solaris Resources beats Fennec Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cara Operations?

Cara Operations (TSE:CARA) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Given Cara Operations' higher probable upside, equities research analysts plainly believe Cara Operations is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cara Operations	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Cara Operations has higher earnings, but lower revenue than Fennec Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Operations	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	C$51.00M	10.43	-C$800.44K	-C$0.29	N/A

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Fennec Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cara Operations	Neutral
Fennec Pharmaceuticals	Neutral

13.1% of Fennec Pharmaceuticals shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cara Operations has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cara Operations' return on equity of 0.00% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cara Operations	N/A	N/A	N/A
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%

Summary

Fennec Pharmaceuticals beats Cara Operations on 6 of the 9 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Cronos Group?

Fennec Pharmaceuticals (TSE:FRX) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Fennec Pharmaceuticals has a beta of 3.522795, meaning that its stock price is 252% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.134248, meaning that its stock price is 13% more volatile than the broader market.

Cronos Group has a consensus price target of C$4.75, indicating a potential upside of 19.05%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Fennec Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	10.43	-C$800.44K	-C$0.29	N/A
Cronos Group	C$159.54M	9.35	-C$32.78M	N/A	N/A

Cronos Group has a net margin of -1.29% compared to Fennec Pharmaceuticals' net margin of -17.22%. Cronos Group's return on equity of -0.19% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Cronos Group	-1.29%	-0.19%	-3.73%

13.1% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Cronos Group shares are owned by institutional investors. 16.2% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Cronos Group	Neutral

Summary

Fennec Pharmaceuticals beats Cronos Group on 8 of the 14 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to Tilray Brands?

Fennec Pharmaceuticals (TSE:FRX) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

13.1% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of Tilray Brands shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Fennec Pharmaceuticals has a net margin of -17.22% compared to Tilray Brands' net margin of -158.75%. Fennec Pharmaceuticals' return on equity of -58.09% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
Tilray Brands	-158.75%	-88.06%	-1.41%

Tilray Brands has a consensus target price of C$13.30, suggesting a potential upside of 103.99%. Given Tilray Brands' higher probable upside, analysts clearly believe Tilray Brands is more favorable than Fennec Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fennec Pharmaceuticals has a beta of 3.522795, indicating that its share price is 252% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.0845, indicating that its share price is 208% more volatile than the broader market.

Fennec Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	10.43	-C$800.44K	-C$0.29	N/A
Tilray Brands	C$858.28M	0.94	-C$183.24M	-C$14.63	N/A

In the previous week, Tilray Brands had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 1 mentions for Tilray Brands and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled Tilray Brands'average media sentiment score.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
Tilray Brands	Neutral

Summary

Fennec Pharmaceuticals beats Tilray Brands on 11 of the 15 factors compared between the two stocks.

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Fennec Pharmaceuticals (TSE:FRX) and International Tower Hill Mines (TSE:ITH) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

International Tower Hill Mines has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -17.22%. International Tower Hill Mines' return on equity of -1.99% beat Fennec Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fennec Pharmaceuticals	-17.22%	-58.09%	8.88%
International Tower Hill Mines	N/A	-1.99%	-3.65%

In the previous week, International Tower Hill Mines had 1 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 1 mentions for International Tower Hill Mines and 0 mentions for Fennec Pharmaceuticals. Fennec Pharmaceuticals' average media sentiment score of 0.00 equaled International Tower Hill Mines'average media sentiment score.

Company	Overall Sentiment
Fennec Pharmaceuticals	Neutral
International Tower Hill Mines	Neutral

13.1% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 9.0% of International Tower Hill Mines shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of International Tower Hill Mines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
International Tower Hill Mines	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Fennec Pharmaceuticals has a beta of 3.522795, indicating that its stock price is 252% more volatile than the broader market. Comparatively, International Tower Hill Mines has a beta of 2.117403, indicating that its stock price is 112% more volatile than the broader market.

Fennec Pharmaceuticals has higher revenue and earnings than International Tower Hill Mines. International Tower Hill Mines is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fennec Pharmaceuticals	C$51.00M	10.43	-C$800.44K	-C$0.29	N/A
International Tower Hill Mines	N/A	N/A	-C$2.36M	-C$0.01	N/A

Summary

Fennec Pharmaceuticals beats International Tower Hill Mines on 9 of the 13 factors compared between the two stocks.

Get Fennec Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRX vs. The Competition

Export

Metric	Fennec Pharmaceuticals	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$532.17M	C$516.65M	C$7.18B	C$13.07B
Dividend Yield	2.02%	3.88%	2.67%	6.18%
P/E Ratio	-52.83	3.09	28.02	36.51
Price / Sales	10.43	6,669.11	534.82	10.34
Price / Cash	11.66	13.13	49.26	82.29
Price / Book	14.00	88.67	10.96	4.52
Net Income	-C$800.44K	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	0.52%	0.17%	2.12%	1.85%
1 Month Performance	20.44%	2.10%	5.25%	1.71%
1 Year Performance	25.99%	68.02%	33.29%	36.40%

Fennec Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRX Fennec Pharmaceuticals	N/A	C$15.32 flat	N/A	N/A	C$532.17M	C$51.00M	N/A	10
SLS Solaris Resources	1.373 of 5 stars	C$11.82 +2.6%	C$19.50 +65.0%	+64.1%	C$1.97B	N/A	N/A	10	Gap Down
CARA Cara Operations	N/A	N/A	N/A	N/A	C$1.62B	N/A	N/A	80
CRON Cronos Group	1.9051 of 5 stars	C$3.98 +2.6%	C$4.75 +19.3%	+44.6%	C$1.49B	C$159.54M	N/A	450	Gap Up
TLRY Tilray Brands	1.1232 of 5 stars	C$6.56 +3.5%	C$13.30 +102.7%	-2.7%	C$792.57M	C$858.28M	N/A	2,650

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:FRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. SLS, CARA, CRON, TLRY, and ITH

How does Fennec Pharmaceuticals compare to Solaris Resources?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fennec Pharmaceuticals (FRX) Competitors

FRX vs. SLS, CARA, CRON, TLRY, and ITH

How does Fennec Pharmaceuticals compare to Solaris Resources?

Do analysts prefer FRX or SLS?

Which has better valuation & earnings, FRX or SLS?

Is FRX or SLS more profitable?

Do insiders and institutionals believe in FRX or SLS?

Does the media prefer FRX or SLS?

Which has more volatility and risk, FRX or SLS?

Summary

How does Fennec Pharmaceuticals compare to Cara Operations?

Do analysts recommend CARA or FRX?

Which has preferable valuation & earnings, CARA or FRX?

Does the media favor CARA or FRX?

Do insiders & institutionals have more ownership in CARA or FRX?

Is CARA or FRX more profitable?

Summary

How does Fennec Pharmaceuticals compare to Cronos Group?

Which has more volatility and risk, FRX or CRON?

Do analysts recommend FRX or CRON?

Which has higher earnings and valuation, FRX or CRON?

Is FRX or CRON more profitable?

Do institutionals and insiders have more ownership in FRX or CRON?

Does the media prefer FRX or CRON?

Summary

How does Fennec Pharmaceuticals compare to Tilray Brands?

Do insiders and institutionals hold more shares of FRX or TLRY?

Is FRX or TLRY more profitable?

Do analysts prefer FRX or TLRY?

Which has more risk and volatility, FRX or TLRY?

Which has higher valuation and earnings, FRX or TLRY?

Does the media refer more to FRX or TLRY?

Summary

How does Fennec Pharmaceuticals compare to International Tower Hill Mines?

Is FRX or ITH more profitable?

Does the media prefer FRX or ITH?

Do insiders & institutionals believe in FRX or ITH?

Do analysts prefer FRX or ITH?

Which has more volatility and risk, FRX or ITH?

Which has preferable earnings & valuation, FRX or ITH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX vs. The Competition

Fennec Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools